Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 134.92 Million EUR | 1.54% |
| 2022 | 150.3 Million EUR | -32.16% |
| 2021 | 221.55 Million EUR | 99.37% |
| 2020 | 111.12 Million EUR | 44.42% |
| 2019 | 76.94 Million EUR | 21.49% |
| 2018 | 63.33 Million EUR | 0.11% |
| 2017 | 63.26 Million EUR | -32.29% |
| 2016 | 93.43 Million EUR | 81.9% |
| 2015 | 51.36 Million EUR | 17.98% |
| 2014 | 43.53 Million EUR | 20.75% |
| 2013 | 36.05 Million EUR | 121.67% |
| 2012 | 16.26 Million EUR | 88.09% |
| 2011 | 8.64 Million EUR | -48.57% |
| 2010 | 16.81 Million EUR | 397.1% |
| 2009 | 3.38 Million EUR | -11.63% |
| 2008 | 3.82 Million EUR | -3.55% |
| 2007 | 3.96 Million EUR | 117.54% |
| 2006 | 1.82 Million EUR | -54.01% |
| 2005 | 3.96 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 39.57 Million EUR | 0.01% |
| 2024 Q1 | 36.13 Million EUR | -20.13% |
| 2023 Q4 | 45.24 Million EUR | 14.86% |
| 2023 Q2 | 25.19 Million EUR | -14.87% |
| 2023 Q3 | 39.38 Million EUR | 56.31% |
| 2023 FY | 152.62 Million EUR | 1.54% |
| 2023 Q1 | 29.6 Million EUR | -35.7% |
| 2022 Q2 | 45.69 Million EUR | 73.04% |
| 2022 Q1 | 26.4 Million EUR | -64.16% |
| 2022 FY | 150.3 Million EUR | -32.16% |
| 2022 Q4 | 46.03 Million EUR | 43.14% |
| 2022 Q3 | 32.16 Million EUR | -29.62% |
| 2021 Q1 | 39.7 Million EUR | 13.67% |
| 2021 Q2 | 59.17 Million EUR | 49.03% |
| 2021 FY | 221.55 Million EUR | 99.37% |
| 2021 Q4 | 73.69 Million EUR | 50.42% |
| 2021 Q3 | 48.99 Million EUR | -17.2% |
| 2020 Q2 | 25.64 Million EUR | 11.26% |
| 2020 Q4 | 34.93 Million EUR | 26.97% |
| 2020 FY | 111.12 Million EUR | 44.42% |
| 2020 Q1 | 23.04 Million EUR | -10.37% |
| 2020 Q3 | 27.51 Million EUR | 7.29% |
| 2019 Q2 | 16.74 Million EUR | 1.95% |
| 2019 Q4 | 25.71 Million EUR | 42.3% |
| 2019 FY | 76.94 Million EUR | 21.49% |
| 2019 Q1 | 16.42 Million EUR | -9.68% |
| 2019 Q3 | 18.07 Million EUR | 7.93% |
| 2018 Q1 | 15.84 Million EUR | -16.14% |
| 2018 FY | 63.33 Million EUR | 0.11% |
| 2018 Q4 | 18.18 Million EUR | 45.65% |
| 2018 Q3 | 12.48 Million EUR | -25.83% |
| 2018 Q2 | 16.83 Million EUR | 6.26% |
| 2017 FY | 63.26 Million EUR | -32.29% |
| 2017 Q4 | 18.88 Million EUR | 12.6% |
| 2017 Q2 | 12.95 Million EUR | -11.54% |
| 2017 Q3 | 16.77 Million EUR | 29.48% |
| 2017 Q1 | 14.64 Million EUR | -10.16% |
| 2016 Q1 | 13.54 Million EUR | -5.63% |
| 2016 FY | 93.43 Million EUR | 81.9% |
| 2016 Q4 | 16.3 Million EUR | 15.4% |
| 2016 Q3 | 14.12 Million EUR | -71.43% |
| 2016 Q2 | 49.45 Million EUR | 265.05% |
| 2015 Q2 | 14.49 Million EUR | 40.46% |
| 2015 Q1 | 10.31 Million EUR | -27.8% |
| 2015 FY | 51.36 Million EUR | 17.98% |
| 2015 Q4 | 14.35 Million EUR | 17.64% |
| 2015 Q3 | 12.2 Million EUR | -15.79% |
| 2014 Q4 | 14.28 Million EUR | 82.14% |
| 2014 Q3 | 7.84 Million EUR | -28.87% |
| 2014 Q1 | 10.37 Million EUR | 41.11% |
| 2014 FY | 43.53 Million EUR | 20.75% |
| 2014 Q2 | 11.02 Million EUR | 6.35% |
| 2013 Q2 | 8.47 Million EUR | 167.98% |
| 2013 Q3 | 16.8 Million EUR | 98.42% |
| 2013 Q1 | 3.16 Million EUR | -29.28% |
| 2013 FY | 36.05 Million EUR | 121.67% |
| 2013 Q4 | 7.34 Million EUR | -56.28% |
| 2012 Q4 | 4.47 Million EUR | 29.83% |
| 2012 Q3 | 3.44 Million EUR | 0.0% |
| 2012 FY | 16.26 Million EUR | 88.09% |
| 2011 FY | 8.64 Million EUR | -48.57% |
| 2010 FY | 16.81 Million EUR | 397.1% |
| 2009 FY | 3.38 Million EUR | -11.63% |
| 2008 FY | 3.82 Million EUR | -3.55% |
| 2007 FY | 3.96 Million EUR | 117.54% |
| 2006 FY | 1.82 Million EUR | -54.01% |
| 2005 FY | 3.96 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -9024.18% |
| CSL Limited | 3.44 Billion USD | 96.088% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -55.469% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2643.521% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -51451.623% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -356.549% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -262.157% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -8883.56% |
| Mesoblast Limited | 5.9 Million USD | -2186.073% |
| Marizyme, Inc. | 19.23 Million USD | -601.274% |
| Genus plc | 147.7 Million USD | 8.65% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1436.854% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -9957.359% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1517.988% |
| ContraFect Corporation | 56.88 Million USD | -137.171% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -2960.423% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.7 Million USD | -257.801% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -4735.367% |
| MultiCell Technologies, Inc. | 567.42 USD | -23778406.221% |
| Accustem Sciences Inc. | 3.74 Million USD | -3501.412% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -56.989% |
| EV Biologics, Inc. | 531.96 Thousand USD | -25263.466% |
| Q BioMed Inc. | 3.43 Million USD | -3826.058% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -445.919% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -5035.028% |
| Biomind Labs Inc. | 994.18 Thousand USD | -13471.358% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1908.391% |
| Skye Bioscience, Inc. | 13.54 Million USD | -895.929% |
| SQZ Biotechnologies Company | 85.61 Million USD | -57.587% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 539796.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2575.978% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -4526.65% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -742.736% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -34534.439% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 40.164% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -6485.819% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -7252.426% |
| GB Sciences, Inc. | 1.42 Million USD | -9398.285% |
| Alpha Cognition Inc. | 9.7 Million USD | -1290.166% |
| argenx SE | 1.53 Billion USD | 91.202% |
| HST Global, Inc. | 140.9 Thousand USD | -95653.937% |
| Halberd Corporation | 74.84 Thousand USD | -180178.453% |
| Enzolytics Inc. | 2.17 Million USD | -6090.574% |
| Resverlogix Corp. | 12.71 Million USD | -961.391% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -3595.832% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -134.896% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -35.834% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -12823.755% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -7567.539% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -5510.299% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -7136.975% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -8442.981% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -3862.55% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1745.679% |
| ONE Bio Corp. | 6.44 Million USD | -1993.828% |
| Zenith Capital Corp. | 8.94 Million USD | -1408.711% |
| Genscript Biotech Corporation | 825.34 Million USD | 83.652% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -774390.557% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -5395.176% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -78568.758% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -6923.977% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -11894.204% |
| Agentix Corp. | 1.37 Million USD | -9735.86% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 2.41 Million USD | -5498.246% |
| Helix BioMedix, Inc. | 1.97 Million USD | -6741.87% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1141.594% |
| BioStem Technologies, Inc. | 22.97 Million USD | -487.269% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -74244.436% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -10003.405% |
| LadRx Corporation | 3.81 Million USD | -3439.648% |
| Cell Source, Inc. | 4.32 Million USD | -3019.381% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -32374.325% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -14509.912% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -14509.912% |
| NovAccess Global Inc. | 2.46 Million USD | -5369.683% |
| Affymax, Inc. | 39.38 Million USD | -242.568% |
| Itoco Inc. | 919.14 Thousand USD | -14579.326% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3083.361% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -11957.551% |
| CytoDyn Inc. | 18.05 Million USD | -647.17% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -535972.152% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -61207.355% |
| Qrons Inc. | 643.67 Thousand USD | -20861.445% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -9403.082% |
| SYBLEU INC | 160.87 Thousand USD | -83768.321% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -5950.732% |
| Rebus Holdings, Inc. | 664 Thousand USD | -20219.88% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -7328.427% |
| Mobile Lads Corp. | 554.54 Thousand USD | -24230.533% |
| International Stem Cell Corporation | 5.27 Million USD | -2459.742% |
| Bioxytran, Inc. | 3.82 Million USD | -3431.906% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -256204.852% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -663145.342% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -272.04% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -8238.937% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -18236.176% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4236.998% |
| Neutra Corp. | 243.82 Thousand USD | -55237.317% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -672.893% |
| PureTech Health plc | 144.59 Million USD | 6.69% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -558.491% |
| IXICO plc | 4.7 Million USD | -2766.454% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1433.75% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -14.587% |
| CSL Limited | 3.89 Billion USD | 96.534% |
| Cellectis S.A. | 97.32 Million USD | -38.64% |